Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
Journal
Clinical Cancer Research
Journal Volume
14
Journal Issue
15
Start Page
4877
End Page
4882
Date Issued
2008
Author(s)
Wu J.-Y.
Gow C.-H.
Abstract
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib, we investigated the clinical features of lung cancer in patients with exon 20 mutations and analyzed the gefitinib treatment response. Experimental Design: We surveyed the clinical data and mutational studies of NSCLC patients with EGFR exon 20 mutations in the National Taiwan University Hospital and reviewed the literature reports about EGFR exon 20 mutations and the gefitinib treatment response. Results: Twenty-three patients with mutations in exon 20 were identified. Nine (39%) had coexisting mutations in EGFR exons other than exon 20. Sixteen patients received gefitinib treatment, and a response was noted in 4 patients. The gefitinib response rate of NSCLC with exon 20 mutations was 25%, far lower than those with deletions in exon 19 and L858R mutations. Interestingly, different exon 20 mutations and coexisting mutations seemed to have a different influence on gefitinib response. Conclusions: EGFR exon 20 mutations of NSCLC patients result in poorer responsiveness to gefitinib treatment, but variability exists between different individuals. ? 2008 American Association for Cancer Research.
Other Subjects
epidermal growth factor receptor; gefitinib; antineoplastic agent; epidermal growth factor receptor; gefitinib; quinazoline derivative; adult; aged; article; bone scintiscanning; bronchoscopy; cancer patient; cancer staging; clinical article; clinical feature; clinical study; clinical trial; computer assisted tomography; controlled study; disease course; drug response; exon; female; gene identification; gene mutation; genetic analysis; human; human tissue; lung non small cell cancer; male; priority journal; thorax radiography; drug resistance; genetics; lung tumor; middle aged; mutation; treatment outcome; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, Epidermal Growth Factor; Treatment Outcome
Type
journal article